Introduction
Histone deacetylases (HDACs) are regarded as highly attractive targets for cancer drug discovery. 1 Hyperacetylation induced by HDAC inhibitors leads to changes in gene expression and functional modifications of non-histone proteins, thereby triggering antitumor pathways. Well characterized HDAC inhibitors such as trichostatin A (TSA, 1), suberanilohydroxamic acid (SAHA,
2) and pyridin-3-ylmethyl-N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]-carbamate (MS-275,

3)
2, 3 ( Figure 1 ) typically contain three structural features that are thought to be required for optimal activity: an aromatic cap group, an aliphatic linker chain and a zinc binding group (ZBG). Based on molecular modeling studies involving the histone deacetylase-like protein (HDLP), these molecules appear to bind in a pocket in the HDAC active site that includes a channel region flanked by a zinc ion on one end, and a region that binds the cap group on the other end. In this model, the aromatic group and aliphatic chain of the inhibitor are buried in the enzyme pocket in such a way that the metal binding moiety coordinates the catalytic zinc ion. 4 Structural studies to identify novel HDAC inhibitors has focused primarily on modifications to the aliphatic linker or the aromatic cap group, while less attention has been paid to the metal binding group, which is typically either a hydroxamic acid or a benzamide. However, hydroxamates suffer from low bioavailability 5, 6 and significant off-target effects 7, 8 that limit their clinical use. Similarly, benzamides contain an aniline moiety that may generate toxic metabolites in vivo. Therefore there is a need to identify HDAC inhibitors with novel ZBGs that possess minimal toxicity and improved pharmacokinetic profiles. To address the need for novel ZBGs, we initiated a search for a moiety that would retain the zinc-binding properties and enzyme inhibitory activity of the benzamide functional group. We now report a structurally novel ZBG, 2-(oxazole-2-yl)phenol, and its incorporation into a series of analogues that are potent HDAC inhibitors. This novel ZBG features an o-hydroxyphenyl group that is directly connected to an oxazole aromatic ring to produce a cation binding site. The 2-(oxazole-2-yl)phenol ZBG structurally mimics the benzamide ZBG, but does not contain an aniline moiety that can potentially generate toxic metabolites in vivo. 
Chemistry
The 2-(oxazole-2-yl)phenol HDAC inhibitor base structure can be synthesized via a facile one-pot reaction procedure 10 that is highly amenable to compound library development. The synthesis of the proposed 2-(oxazole-2-yl)phenol-based HDAC inhibitors is shown in Scheme 1. The condensation of salicylaldehyde 4 with L-serine methyl ester hydrochloride 5 yielded the intermediate 1,3-oxazolidine 6, which was then oxidized in situ in the presence of BrCCl 3 /DBU to afford the corresponding 1,3-oxazole methyl ester 7. The methyl ester 7 was then cleaved in the presence of lithium hydroxide to form the corresponding carboxylate 8, which was coupled to the appropriate amines to afford the desired target molecules 9-24. Complete experimental details for the synthesis of 9-24 appear in the Supplemental Information section.
Enzyme Inhibition
Compounds 9-24 were evaluated for their ability to act as inhibitors of human HDAC. Inhibitory activity was initially surveyed against all 11 human recombinant HDAC isoforms at an initial concentration of 20 µM (Table S1 ). In general, none of the (oxazole-2-yl)phenol analogues 9-24 produced > 50% inhibition of HDACs 3,4,5,7,8, 9 and 11, with the exception of 15 (49.9% inhibition of HDAC11), 19 (55.5% inhibition of HDAC4, 70.2% inhibition of HDAC9 and 69.9% inhibition of HDAC11) and 22 (49.2% inhibition of HDAC11) (Table S1 ). Compounds 9, 10, 13, 14 and 22 produced > 50% inhibition against HDAC1, but among these HDAC1 inhibitors, only 10, 14 and 22 inhibited HDAC2 by 50% or more. Analogues 9, 10, 12-15, 22 and 24 produced roughly equivalent inhibition of the class IIb HDACs (6 and 10), while 11 and 16-19, 22 and 23 showed a slight selectivity for either HDAC6 or HDAC 10. Compounds 19, 24 and especially 23 appeared to be moderately selective for HDAC10. Although these selectivity data are of interest, the compound library described in this manuscript is too small to generate meaningful structure/activity relationships for the oxazole-2-yl)phenol HDAC inhibitors. The structures for 9-24 and inhibition data for HDACs 1, 2, 6 and 10 appear in Table 1 .
Scheme 1. Synthesis of 2-(oxazol-2-yl)phenol-based HDAC inhibitors 9-24.
Figure 2. Dose response curves for compounds 9 , 10 , 11 and 14 against cultured MV-4-11 leukemia cells. Cells were exposed to inhibitors for 24 hours at concentrations ranging from 1 to 100 µM. Each data point is the average of 3 determinations that in each case varied by 5% or less. 
Cellular Effects
We next examined the cellular effects of compounds 9-14 in the MV-4-11 leukemia cell line. The results of these studies are shown in Figure 2 . Compound 9, in which the cap group was a single phenyl moiety, inhibited the growth of MV-4-11 leukemia cells with an IC 50 value of 25 µM The most active of these six compounds, 10, possessed a 1,1-diphenylmethyl group, and had an IC 50 value of 7.5 µM against MV-4-11 cells. Addi Addition of a methylene group to 10 produced the corresponding diphenylethyl analogue 11, which increased the IC 50 value to 40 µM. Addition of a second methylene group to 11 produced the corresponding diphenylpropyl analogue 12, which was inactive as a growth inhibitor in the MV-4-11 cell line (data not shown). Replacing the phenyl group in 9 with a biphenyl (13) or a 4-phenylbenzyl group (14) resulted in an inactive growth inhibitor (data for 13 not shown). These preliminary studies suggest that the configuration and electronic character of the cap group are critical factors in determining activity in this series. Intracellular histone acetylation status is a direct indicator of class I HDAC inhibition, and histone 3 lysine 9 (H3K9) acetylation plays a dominant role in histone deposition and chromatin assembly in some organisms. 11, 12 To further investigate the cellular effects of compound 10, we measured histone acetylation status in MV-4-11 leukemia cells by Western blotting. The results of these studies appear in Figure 3 , lane 3. At 2.5 µM, compound 10 produced an increase in H3K9 acetylation equivalent to that produced by 0.5 µM SAHA. These results are consistent with our earlier observations for differences in potency between hydroxamic acid-and benzamide-based histone deacetylase inhibitors. 13, 14 The cyclin-dependent kinase inhibitor p21 WAF1/CIP1 is well established as an inhibitor of cell cycle progression owing to its ability to inhibit (CDK)-cyclin complexes and proliferating cell nuclear antigen (PCNA). 15, 16 Changes in p21 WAF1/CIP1 are commonly measured to determine the effect of HDAC inhibitors on the re-expression of aberrantly silenced genes in leukemia cell lines. To determine whether intracellular inhibition of HDAC by 10 resulted in epigenetic changes in gene expression in MV-4-11 leukemia cells, levels of p21 WAF1/CIP1 were also measured by Western blotting. Compound 10 produced a dose-dependent increase in p21 WAF1/CIP1 expression at concentrations between 1.0 and 10.0 µM that paralleled the observed increase in H3K9 acetylation (Figure 3) . Taken together, these data strongly suggest that 10 causes significant up regulation of the expression of aberrantly silenced genes in leukemia cells in vitro, which in turn leads to a cytotoxic response. These observations are consistent with data previously published by us 13, 14 and by other research groups. 2, 17 We are currently assessing the antitumor effects of 10 in MV-4-11 leukemia cells in combination with standard antitumor agents such as the deoxynucleotide methyltransferase inhibitor 5-azacytidine. Recent studies have shown that the IC 50 of SAHA against MV4-11 leukemia cells in vitro is 0.7 µM.
18 Thus, the difference in cellular IC 50 value against MV4-11 cells between SAHA and compound 10 (7.5 µM) is 10.7-fold. However, it is important to note that the IC 50 value of SAHA against purified HDAC1 has been reported to be as low as 0.014 µM, 19 and thus its potency in MV4-11 cells is 500 times lower than against the purified enzyme. In fact, nearly allexisting HDAC inhibitors are significantly more potent in enzyme inhibitory assays than in cellular assays. In the case of 10, preparing a solution greater than 20 µM required the addition of more than 1% DMSO, which is a weak HDAC inhibitor. As such, we were unable to determine an accurate IC 50 value for 10 against HDAC1, but the data for 10 in Table 1 suggests that the IC 50 for this isoform is less than 20 µM. The fact that the cellular IC 50 is lower than the enzymatic IC 50 suggests that 10 may be a dual inhibitor with a second mechanism of action, or that it acts by disruption of one of three HDAC1/2 complexes formed at the gene promoter site. 20 In the event that this is true, compound 10 would be the first reported disruptor of the HDAC1/2 complex. Importantly, there is a measurable increase in cellular levels of acetylated H3K9 at 2.5 µM and above (Figure 3) . The fact that this concentration is well below the estimated IC 50 value suggests that a second mechanism, as yet unknown, is the primary driver for the observed increase in acetylated H3K9. The enhanced cellular IC 50 value may also be due to the favorable lipid solubility of 10 (logP = 3.91; ClogP = 4.28; total polar surface area (TPSA) = 75.35 Å 2 ; all other parameters conform to Lipinski's Rule of Five 21 ).
To better understand the molecular basis for the observed biological activity of compound 10, we performed in silico molecular docking experiments using the MOE software package. For our modeling purposes, we used the coordinates of X-ray crystal structure 4LY1 from the Protein Data Bank, which depicts HDAC2 complexed with the benzamide HDAC inhibitor inhibitor 4-(acetylamino)-N-[2-amino-5-(thiophen-2-yl)phenyl]benzamide. 22 This structure was chosen because it featured a benzamide ligand rather than a hydroxamic acid, and because 10 preferentially inhibits HDAC1 and 2. No crystal structure is available for HDAC1, and as such, HDAC2 is the most relevant class I HDAC available. The top ranked binding mode of the inhibitor 10 in the HDAC2 binding site is shown in Figure 4 , Panel A, and the corresponding interaction map is depicted in Figure 4 , Panel B. The zinc ion is held in the active site through coordination with Asp 269 (1.97 Å, Asp 181(1.98 Å) and His 183 (2.02 Å), and a fourth interaction with the phenolic OH in 10 (2.30 Å). We had predicted a bidentate zinc binding this finding we will refine our in silico model when we have inhibitors with greater potency and affinity in hand. Taken together, the in silico data indicates that 1) ligand binding and inhibitory activity for the 2-(oxazole-2-yl)phenol HDAC inhibitors was similar to that of the benzamide class HDAC inhibitors, and both ZBGs exhibited monodentate coordination of the zinc ion; 2) both classes of inhibitors are selective for class I HDACs (especially HDAC1). By contrast, hydroxamate-based HDAC inhibitors are generally more potent than benzamide or 2-(oxazole-2-yl)phenol HDAC inhibitors, most likely because hydroxamates form bidentate zinc coordination, but also due to affinity for HDAC active site residues (see below).
Zinc Binding Affinity
The KA and KD values for the binding of compound 10 to Zn ++ were determined using isothermal calorimetry (ITC)( TA Instruments NanoITC Isothermal Calorimeter, NanoAnalyze software package), 23 and the resulting isotherm is shown in Figure 5 . 23 These data indicate that the 2-(oxazole-2-yl)phenol moiety binds Zn++ more efficiently than the hydroxamic acid moiety found in SAHA. Importantly, the binding of SAHA to HDAC8 is much more efficient KA = 1.72 X 10 3 M -1 , K D + 0.58 µM) 24 suggesting that the attraction of SAHA to the HDAC8 active site is significantly strengthened by interaction of the compound with enzyme active site residues. Because compound 10 has very poor inhibitory activity against HDAC8, we did not determine the equilibrium constant for this interaction, since a direct comparison to SAHA/HDAC8 affinity was not possible. Because 10 is significantly less potent than SAHA against HDAC isoforms 1, 2, 6 and 10, it is likely that the contacts between the enzyme and 10 are not optimal and contribute less to the binding affinity of the inhibitor, even though it is a more efficient Zn ++ binder. As such, the synthesis of additional 2-(oxazol-2-yl)phenol HDAC inhibitors is an ongoing concern in our laboratory, and should result in the discovery of more potent analogues in the series.
Conclusion
In conclusion, we have characterized a new chemical class of HDAC inhibitor containing the 2-(oxazole-2-yl)phenol ZBG. In general, these analogues produce selective inhibition against HDAC1 (and HDAC2 in some instances) and class the IIb HDACs 6 and 10. Unlike almost all other HDAC inhibitors, compound 10 has a lower IC 50 value in cellular assays than in a recombinant HDAC enzyme assay. This observation indicates that 10 could act by disrupting the HDAC1/2 epigenetic complex, or it could be a dual inhibitor with a second mechanism of action. Compound 10 shows a distinct isoform selectivity, and induces significant up regulation in H3K9 acetylation and p21 WAF1/CIP1 re-expression. Molecular modeling suggests that 10 assumes a similar zinc binding pattern to benzamide HDAC inhibitors in the HDAC2 active site. Based on these observations, hit-to-lead and lead optimization studies for 2-(oxazole-2-yl)phenol-based HDAC inhibitors are an ongoing concern in our laboratories.
